Chicago Sun-Times

CDC GIVES OK TO PFIZER BOOSTERS FOR 16-YEAR-OLDS

- BY LAURAN NEERGAARD AND MIKE STOBBE

U.S. health authoritie­s again expanded the nation’s booster campaign Thursday, opening extra doses of Pfizer’s COVID-19 vaccine to several million 16- and 17-year-olds.

The U.S. and many other nations already were urging adults to get booster shots to pump up immunity that can wane months after vaccinatio­n, calls that intensifie­d with the discovery of the worrisome new Omicron variant.

On Thursday, the Food and Drug Administra­tion gave emergency authorizat­ion for 16- and 17-year-olds to get a third dose of the vaccine made by Pfizer and its partner BioNTech — once they’re six months past their last dose. And hours later, the Centers for Disease Control and Prevention lifted the last barrier as Dr. Rochelle Walensky, the agency’s director, issued a statement strongly encouragin­g those teens to get their booster as soon as it’s time.

Boosters are important considerin­g that protection against infection wanes over time and “we’re facing a variant that has the potential to require more immunity to be protected,” Walensky told The Associated Press.

About 200 million Americans are fully vaccinated, including about 4.7 million 16- and 17-year-olds, many of whom got their first shots in the spring and would be eligible for a booster.

“Vaccinatio­n and getting a booster when eligible, along with other preventive measures like masking and avoiding large crowds and poorly ventilated spaces, remain our most effective methods for fighting COVID-19,” Dr. Janet Woodcock, acting FDA commission­er, said in a statement.

The Pfizer vaccine is the only option in the U.S. for anyone younger than 18, either for initial vaccinatio­n or for use as a booster. It’s not yet clear if or when teens younger than 16 might need a third Pfizer dose. But Walensky said the CDC and FDA would closely watch data on 12to 15-year-olds because if they eventually need boosters, “we again will want to act swiftly.”

Vaccinatio­ns for children as young as 5 just began last month, using special low-dose Pfizer shots. By this week, about 5 million 5to 11-year-olds had gotten a first dose.

The extra-contagious Delta variant is causing nearly all COVID-19 infections in the U.S., and in much of the world. It’s not yet clear how vaccines will hold up against the new and markedly different Omicron mutant. But there’s strong evidence that boosters offer a jump in protection against Delta-caused infections, currently the biggest threat.

“The booster vaccinatio­n increases the level of immunity and dramatical­ly improves protection against COVID-19 in all age groups studied so far,” BioNTech CEO Ugur Sahin said in a statement.

 ?? STEVEN SENNE/AP ?? The Pfizer vaccine is the only option in the U.S. for anyone younger than 18, either for initial vaccinatio­n or for use as a booster.
STEVEN SENNE/AP The Pfizer vaccine is the only option in the U.S. for anyone younger than 18, either for initial vaccinatio­n or for use as a booster.

Newspapers in English

Newspapers from United States